Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Triton in connection with the divestment of Norstat to Nalka Invest
Mandate

Vinge advises Triton in connection with the divestment of Norstat to Nalka Invest

April 12, 2024 M&A Banking and Finance Restructuring and Insolvency

Vinge advises Triton Smaller Mid-Cap Fund I (“Triton”) in connection with the divestment of Norstat, a leading data collector for market research, to Nalka Invest.

Norstat is one of the leading data collectors for market research and insight in Europe. Norstat serves more than 2,000 market research firms, private and public end-clients, media agencies, publishers, and consultancies across different industries. The company was established in Norway in 1997 and has since grown its geographical presence to include Denmark, Sweden, Finland, Estonia, Latvia, Lithuania, Poland, Germany, the United Kingdom, France, Switzerland, the Netherlands, Austria and Italy.

The transaction is subject to applicable regulatory approvals.

Vinge’s team consisted mainly of Christina Kokko, Johanna Wiberg, Amanda Steen, Robin Fagerström, Filip Magnusson and Saga Meyer Viklund (M&A), Helena Göransson (Banking and Finance), Daniel Wendelsson, David Olander and Alva Chambert (Regulatory) and Ellinore Boström Andersson, Gabriella Balbo and Fanny Askelöf (Transaction Support Specialists).

Related

Vinge advises Sobro on its investment in Västkustens Konstruktionsbyrå

 Västkustens Konstruktionsbyrå has decided to broaden its ownership structure by bringing in Sobro as a new co-partner and majority shareholder. The founders will remain with the company as the CEO and CTO respectively, and as significant shareholders. Västkustens Konstruktionsbyrå is an engineering consultancy company based in Gothenburg with cutting-edge expertise in project management, civil engineering and design.
April 23, 2026

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of SEK 350 million before transaction costs.
April 22, 2026

Vinge has advised Alder on the establishment of Alder Strategic Opportunities Fund I and on a fund credit facility agreement in connection with the fundraising

 Vinge has advised Alder on the establishment of the continuation fund Alder Strategic Opportunities Fund I AB. In connection with the establishment, the fund acquires the portfolio companies SI and SMG from Alder II. Vinge also advised Alder on the entering into of a fund credit facility agreement with SEB.
April 20, 2026